<DOC>
	<DOCNO>NCT03005327</DOCNO>
	<brief_summary>The overall objective evaluate X4P-001 treatment patient WHIM Syndrome .</brief_summary>
	<brief_title>A Trial X4P-001 Patients With WHIM Syndrome</brief_title>
	<detailed_description>The primary objective Phase 2 determine safety , tolerability , dose selection X4P‑001 Phase 3 patient WHIM syndrome . The primary objective Phase 3 demonstrate X4P-001 effective treatment patient WHIM syndrome , demonstrate sustained increase circulate neutrophils lymphocyte associate improvement clinical manifestation WHIM syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<criteria>To eligible study , patient must meet follow inclusion criterion : 1 . Be least 18 year age Phase 2 ; least 13 year age Phase 3 . 2 . Has sign current approve informed consent form ; patient 18 year age sign approve informed assent form must also sign parental/legal guardian consent . 3 . Has genotypeconfirmed mutation CXCR4 consistent WHIM syndrome . 4 . For woman childbearing potential men , agree use effective contraceptive method screen , study , least 4 week last dose study drug . 5 . Be willing able comply protocol . In criterion , `` prior Day 1 '' refers Day 1 treatment Phase 2 Observation Period Phase 3 . Patients follow excluded participation study : 1 . Has know systemic hypersensitivity X4P001 . 2 . Is pregnant nursing . 3 . Has , screening , laboratory test meet one follow criterion : A positive indeterminate screen test antibody human immunodeficiency virus ( HIV ) type 1 2 . A positive antibody test hepatitis C virus ( HCV ) , unless document detectable viral load two independent sample . A positive test hepatitis B surface antigen ( HBsAg ) . 4 . Has , screening , safety laboratory test meet one follow criterion : Hemoglobin &lt; 8.0 g/dL Platelets &lt; 75,000/μL Creatinine &gt; 2.0 x upper limit normal ( ULN ) Serum aspartate transaminase ( AST ) &gt; 2.5x ULN Serum alanine transaminase ( ALT ) &gt; 2.5x ULN Total bilirubin &gt; 1.5x ULN ( unless due Gilbert 's Syndrome ) International normalize ratio ( INR ) &gt; 1.5x ULN 5 . Has , within 6 month prior Day 1 , receive Plerixafor ( openlabel blind ) treatment WHIM Syndrome . 6 . Has , within 4 week prior Day 1 , surgery require general anesthesia . 7 . Has , within 2 week prior Day 1 , receive following treatment : GCSF granulocytemacrophage colonystimulating factor ( GMCSF ) Intravenous immunoglobulin ( IVIG ) Corticosteroids ( &gt; 10 mg prednisone equivalent per day ) Investigational therapy discuss Medical Monitor 8 . Has , within 2 week prior Day 1 , receive medication prohibit base Cytochrome P450 3A4 ( CYP3A4 ) and/or Pglycoprotein 1 ( P‑gp ) interaction . 9 . Has , plan initiation study drug , uncontrolled active infection ( exclude wart ) . 10 . Has medical personal condition , opinion Investigator , may potentially compromise safety compliance patient , may preclude patient 's successful completion clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>